The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.
Interventional cardiology continues to evolve, driven by rapid advancements in technology. George Dangas, MD, discussed some of the specialty's biggest ongoing trends with Cardiovascular Business.
Researchers have made it a priority to learn as much about the durability of TAVR valves as possible. A new study in JACC: Cardiovascular Interventions used updated VARC-3 definitions to identify signs of hemodynamic valve deterioration in nearly 2,500 patients.
How have recent FDA approvals for Edwards Lifesciences and Abbott changed patient care? Andrew Rassi, MD, answered that question—and many more—in a new interview.
There have been a total of 11 incidents so far, including seven injuries and two deaths. Boston Scientific said the agent can still be used if operators follow specific instructions during lower GI bleed embolization procedures.
Biga, who originally trained as a nurse, specializes in the business side of cardiology. She also emphasized the increasing importance of AI and other new technologies.
The American Society of Nuclear Cardiology (ASNC) says positron emission tomography (PET) nuclear imaging has seen wider adoption in the past few years, and many cardiac imaging experts say it could become the workhorse technology for nuclear cardiac assessments over the next decade.
Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.